论文部分内容阅读
目的 提高人脑胶质瘤过继免疫治疗的效果 ,探索治疗脑胶质瘤的新途径。方法 用植物血凝素 (PHA)、抗CD3单抗 (CD3)和IL 2共同诱导人外周血单个核细胞 (PBMC) ,诱导、扩增新型抗胶质瘤效应细胞PHA CD3AK细胞 ,并与CD3AK细胞在某些生物学方面进行了比较。结果 两组效应细胞增殖曲线均于第 6天达高峰 ,峰值可见 ,PHA CD3AK细胞 >CD3AK (P <0 0 5 ) ;PHA CD3AK细胞扩增倍数明显高于CD3AK细胞 (P <0 0 5 ) ;两组效应细胞于培养的第 6、 8、 10天所测得的杀伤胶质瘤细胞BT32 5活性可见 ,PHA CD3AK细胞 >CD3AK细胞 (P <0 0 5 )。结论 PHA、CD3和IL 2具有协同增强作用 ,使PHA CD3AK细胞成为较CD3AK细胞增殖能力、杀伤活性更强的免疫效应细胞 ,且IL 2用量减少 ,为胶质瘤的过继免疫治疗打下了理论基础
Objective To improve the effect of adoptive immunotherapy in human glioma and explore new ways to treat glioma. Methods Human peripheral blood mononuclear cells (PBMCs) were induced by phytohemagglutinin (PHA), anti-CD3 monoclonal antibody (CD3) and IL2 to induce and amplify a novel anti-glioma effector cell line PHA CD3AK. Cells are compared in some aspects of biology. Results The proliferative curve of effector cells in both groups peaked on the 6th day. The peak value of PH3 CD3AK cells was> CD3AK (P <0.05). The multiplication of PHA CD3AK cells was significantly higher than that of CD3AK cells (P <0 05). The activity of BT32 5 was detected on the 6th, 8th and 10th day after culture. The PHA CD3AK cells> CD3AK cells (P <0 05). Conclusions PHA, CD3 and IL 2 have a synergistic enhancing effect, making PHA CD3AK cells a more effective and more cytotoxic effector than CD3AK cells, and the dosage of IL 2 is reduced, laying a theoretical foundation for the adoptive immunotherapy of gliomas